For example, tumor-infiltrating lymphocytes (TILs), such as CD4+ T cells and CD8+ T cells, have emerged as potential prognostic factors for therapeutic responsiveness to immunotherapy (Vassilakopoulou et al., 2016). The gene discussed is CD8A; the disease is neoplasm.